The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs.
The share issue is directed to a number of selected Swedish and international long-term institutional investors and sector specialist funds, on the basis of a book building procedure conducted by DNB Markets, goetzpartners securities and Zonda Partners.
Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company’s shares are admitted to trading on Nasdaq First North.
Vinge’s team has consisted of Jesper Schönbeck, Johan Winnerblad, Nils Fredrik Dehlin, Amanda Knutsson and Emelie Svanberg.
